C4 Therapeutics (CCCC) Revenue & Revenue Breakdown
C4 Therapeutics Revenue Highlights
C4 Therapeutics Revenue by Period
C4 Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | - | -100.00% |
| 2022-12-31 | $31.10M | -32.08% |
| 2021-12-31 | $45.78M | 37.93% |
| 2020-12-31 | $33.20M | 55.25% |
| 2019-12-31 | $21.38M | 10.42% |
| 2018-12-31 | $19.36M | - |
C4 Therapeutics generated - in revenue during NA 2023, up -100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
C4 Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | - | -100.00% |
| 2024-03-31 | $3.04M | -6.81% |
| 2023-12-31 | $3.26M | -70.55% |
| 2023-09-30 | $11.07M | 315.62% |
| 2023-06-30 | $2.66M | -29.13% |
| 2023-03-31 | $3.76M | 31.71% |
| 2022-12-31 | $2.85M | -57.74% |
| 2022-09-30 | $6.75M | -51.18% |
| 2022-06-30 | $13.83M | 80.74% |
| 2022-03-31 | $7.65M | -61.88% |
| 2021-12-31 | $20.08M | 136.21% |
| 2021-09-30 | $8.50M | -13.10% |
| 2021-06-30 | $9.78M | 31.71% |
| 2021-03-31 | $7.43M | -10.12% |
| 2020-12-31 | $8.26M | -2.19% |
| 2020-09-30 | $8.45M | -12.65% |
| 2020-06-30 | $9.67M | 41.87% |
| 2020-03-31 | $6.82M | -16.97% |
| 2019-12-31 | $8.21M | 53.04% |
| 2019-09-30 | $5.36M | - |
C4 Therapeutics generated - in revenue during Q1 2024, up -100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
C4 Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| KYMR | Kymera Therapeutics | $78.59M | $10.29M |
| ARVN | Arvinas | $78.50M | $76.50M |
| NRIX | Nurix Therapeutics | $76.99M | $12.09M |
| FHTX | Foghorn Therapeutics | $34.16M | $6.89M |
| RVMD | Revolution Medicines, Inc. Warrant | $11.58M | - |
| IPSC | Century Therapeutics | $2.23M | $771.00K |
| STTK | Shattuck Labs | $1.66M | $1.61M |
| RZLT | Rezolute | - | - |
| CGEM | Cullinan Oncology | - | - |
| CCCC | C4 Therapeutics | - | - |
| CYT | Cyteir Therapeutics | - | - |
| ELYM | Eliem Therapeutics | - | - |
| PRLD | Prelude Therapeutics | - | - |
| MLYS | Mineralys Therapeutics | - | - |
| GLUE | Monte Rosa Therapeutics | - | $4.70M |
| EWTX | Edgewise Therapeutics | - | - |
CCCC Revenue FAQ
What is C4 Therapeutics’s yearly revenue?
C4 Therapeutics's yearly revenue for 2023 was $0, representing a decrease of -100.00% compared to 2022. The company's yearly revenue for 2022 was $31.1M, representing a decrease of -32.08% compared to 2021. CCCC's yearly revenue for 2021 was $45.78M, representing an increase of 37.93% compared to 2020.
What is C4 Therapeutics’s quarterly revenue?
C4 Therapeutics's quarterly revenue for Q1 2024 was $0, a -100.00% decrease from the previous quarter (Q4 2023), and a -100.00% decrease year-over-year (Q1 2023). The company's quarterly revenue for Q4 2023 was $3.04M, a -6.81% decrease from the previous quarter (Q3 2023), and a -19.15% decrease year-over-year (Q4 2022). CCCC's quarterly revenue for Q3 2023 was $3.26M, a -70.55% decrease from the previous quarter (Q2 2023), and a 14.26% increase year-over-year (Q3 2022).
What is C4 Therapeutics’s revenue growth rate?
C4 Therapeutics's revenue growth rate for the last 3 years (2021-2023) was -100.00%, and for the last 5 years (2019-2023) was -100.00%.